FGFR1 and acrodermatitis enteropathica: For the development of novel chemotherapeutics against AE, EmFR1 and EmFR2 would thus be highly interesting target molecules although, of course, BIBF 1120 as originally developed against human FGF receptors showed somewhat higher activities against FGFR1 in the Xenopus expression system than against the parasite FGF receptors.